All Stories

  1. Emerging drugs for treating methicillin-resistant Staphylococcus aureus
  2. Management of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics
  3. High prevalence of subclass-specific binding and neutralizing antibodies against Clostridium difficile toxins in adult cystic fibrosis sera: possible mode of immunoprotection against symptomatic C. difficile infection
  4. Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators
  5. Antibiotic therapy and Clostridium difficile infection – primum non nocere – first do no harm
  6. Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model
  7. Editorial Commentary : Critically Ill Patients With Clostridium difficile Infection: Are 2 Antibiotics Better Than One?
  8. Recurrence of dual-strain Clostridium difficile infection in an in vitro human gut model
  9. Comparison of the Vidas C. difficile GDH Automated Enzyme-Linked Fluorescence Immunoassay (ELFA) with Another Commercial Enzyme Immunoassay (EIA) (Quik Chek-60), Two Selective Media, and a PCR Assay forgluDfor Detection of Clostridium difficile in Feca...
  10. Emergence and spread of predominantly community-onset Clostridium difficile PCR ribotype 244 infection in Australia, 2010 to 2012
  11. Clostridium difficile Infection
  12. Diagnostic Pitfalls in Clostridium difficile Infection
  13. Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes
  14. A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections
  15. Development and Validation of an Internationally-Standardized, High-Resolution Capillary Gel-Based Electrophoresis PCR-Ribotyping Protocol for Clostridium difficile
  16. In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile
  17. Reply to ‘Clostridium difficile period of increased incidence in hospitals’
  18. Development of a sporicidal test method for Clostridium difficile
  19. Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID)
  20. Clostridium difficile ribotype 126 in southern Taiwan: A cluster of three symptomatic cases
  21. Lack of Evidence for an Unmet Need to Treat Clostridium difficile Infection in Infants Aged <2 Years: Expert Recommendations on How to Address This Issue
  22. SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model
  23. Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection
  24. Editorial Commentary: The Trials and Tribulations of Treating Clostridium difficile Infection--One Step Backward, One Step Forward, but Still Progress
  25. Effectiveness of deep cleaning followed by hydrogen peroxide decontamination during high Clostridium difficile infection incidence
  26. Antibodies for Treatment of Clostridium difficile Infection
  27. Comparison of planktonic and biofilm-associated communities of Clostridium difficile and indigenous gut microbiota in a triple-stage chemostat gut model
  28. Development and Validation of a Chemostat Gut Model To Study Both Planktonic and Biofilm Modes of Growth of Clostridium difficile and Human Microbiota
  29. International Clostridium difficile animal strain collection and large diversity of animal associated strains
  30. Parameters for the Mathematical Modelling of Clostridium difficile Acquisition and Transmission: A Systematic Review
  31. Evolutionary History of the Clostridium difficile Pathogenicity Locus
  32. Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection
  33. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection
  34. Comparison of Multilocus Variable-Number Tandem-Repeat Analysis and Whole-Genome Sequencing for Investigation of Clostridium difficile Transmission
  35. Diverse Sources of C. difficile Infection Identified on Whole-Genome Sequencing
  36. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure
  37. Conventional therapeutics forClostridium difficileinfection
  38. Clostridium difficile
  39. New guidance on the management of Clostridium difficile infection
  40. Evaluation of the effect of oritavancin on Clostridium difficile spore germination, outgrowth and recovery
  41. Short-Term Genome Stability of Serial Clostridium difficile Ribotype 027 Isolates in an Experimental Gut Model and Recurrent Human Disease
  42. Evaluation of antimicrobial activity of ceftaroline against Clostridium difficile and propensity to induce C. difficile infection in an in vitro human gut model
  43. Relationship Between Bacterial Strain Type, Host Biomarkers, and Mortality in Clostridium difficile Infection
  44. Risk Factors for Clostridium difficile Acquisition in Infants: Importance of Study Design
  45. Regarding "Clostridium Difficile Ribotype Does Not Predict Severe Infection"
  46. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications
  47. Clostridium difficile: A European perspective
  48. Mixed infection by Clostridium difficile in an in vitro model of the human gut
  49. Fidaxomicin: novel antibiotic for Clostridium difficile infection
  50. Emergence and global spread of epidemic healthcare-associated Clostridium difficile
  51. Epidemiology, diagnosis and treatment ofClostridium difficileinfection
  52. Recombinational Switching of the Clostridium difficile S-Layer and a Novel Glycosylation Gene Cluster Revealed by Large-Scale Whole-Genome Sequencing
  53. Hospital and community transmission of Clostridium difficile: a whole genome sequencing study
  54. Morbidity and mortality associated with Clostridium difficile ribotype 078: a case–case study
  55. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection
  56. Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model
  57. Fidaxomicin: a new option for the treatment of Clostridium difficile infection
  58. Changing Epidemiology of Clostridium difficile Infection Following the Introduction of a National Ribotyping-Based Surveillance Scheme in England
  59. Renal Failure and Leukocytosis Are Predictors of a Complicated Course of Clostridium difficile Infection if Measured on Day of Diagnosis
  60. Predictors of First Recurrence of Clostridium difficile Infection: Implications for Initial Management
  61. Policy development for Clostridium difficile
  62. Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model
  63. Diverse Temperate Bacteriophage Carriage in Clostridium difficile 027 Strains
  64. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection
  65. Models for the study of Clostridium difficile infection
  66. Characterisation of Clostridium difficile Hospital Ward–Based Transmission Using Extensive Epidemiological Data and Molecular Typing
  67. Co-amoxiclav induces proliferation and cytotoxin production of Clostridium difficile ribotype 027 in a human gut model
  68. Overcoming barriers to effective recognition and diagnosis of Clostridium difficile infection
  69. Control of the spread of resistance and Clostridium difficile infection
  70. Potential for aerosolization of Clostridium difficile after flushing toilets: the role of toilet lids in reducing environmental contamination risk
  71. A pilot study of rapid benchtop sequencing ofStaphylococcus aureusandClostridium difficilefor outbreak detection and surveillance
  72. Microevolutionary analysis of Clostridium difficile genomes to investigate transmission
  73. Clostridium difficile Mixed Infection and Reinfection: Fig 1
  74. PIN10 Clinical and Economic Burden of Hospital Onset Health Care Facility Acquired Clostridium Difficile Infection (HO-HCFA-CDI) in Europe: A Systematic Review
  75. An Enhanced DNA Fingerprinting Service To Investigate Potential Clostridium difficile Infection Case Clusters Sharing the Same PCR Ribotype
  76. Controlling Clostridium difficile Infection and the Role of Antibiotic Stewardship
  77. Predicting the Severity of Clostridium Difficile Infection
  78. Laboratory diagnosis of Clostridium difficile infection: in a state of transition or confusion or both?
  79. Clinical Clostridium difficile: Clonality and Pathogenicity Locus Diversity
  80. Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model
  81. Nitazoxanide is active against Clostridium difficile strains with reduced susceptibility to metronidazole
  82. Sporicides for Clostridium difficile: the devil is in the detail
  83. Monomicrobial Clostridium difficile bacteraemias and relationship to gut infection
  84. Clostridium difficile infection in Europe: a hospital-based survey
  85. Reference assays for Clostridium difficile infection: one or two gold standards?
  86. Comparison of Real-Time PCR Techniques to Cytotoxigenic Culture Methods for Diagnosing Clostridium difficile Infection
  87. Point-Counterpoint: What Is the Current Role of Algorithmic Approaches for Diagnosis ofClostridium difficileInfection?
  88. New Clinical Practice Guidelines for Clostridium difficile Infection
  89. Relatedness of Human and Animal Clostridium difficile PCR Ribotype 078 Isolates Determined on the Basis of Multilocus Variable-Number Tandem-Repeat Analysis and Tetracycline Resistance
  90. Two-step testing for C. difficile: no answers yet
  91. Infection due to C. difficile ribotype 078: first report of cases in the Republic of Ireland
  92. The Changing Epidemiology of Clostridium difficile Infections
  93. The Potential for Airborne Dispersal of Clostridium difficile from Symptomatic Patients
  94. Guías de práctica clínica para la infección porClostridium difficileen adultos: actualización 2010 realizada por la Sociedad de Salud Epidemiológica de Norteamérica (SHEA) y la Sociedad de Enfermedades Infecciosas de Norteamérica (IDSA)
  95. Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)
  96. Multilocus Sequence Typing ofClostridium difficile
  97. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Data review and recommendations for diagnosing Clostridium difficile-infection (CDI)
  98. Characterization of the Sporulation Initiation Pathway of Clostridium difficile and Its Role in Toxin Production
  99. Comparison of Nine Commercially Available Clostridium difficile Toxin Detection Assays, a Real-Time PCR Assay for C. difficile tcdB, and a Glutamate Dehydrogenase Detection Assay to Cytotoxin Testing and Cytotoxigenic Culture Methods
  100. Clostridium difficile infection: new developments in epidemiology and pathogenesis
  101. Tolevamer Is Not Efficacious in the Neutralization of Cytotoxin in a Human Gut Model of Clostridium difficile Infection
  102. Mecillinam: a low-risk antimicrobial agent for induction of Clostridium difficile infection in an in vitro human gut model
  103. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model
  104. Clostridium difficile Type O27, Coping with a More Virulent Strain
  105. Effects of Exposure of Clostridium difficile PCR Ribotypes 027 and 001 to Fluoroquinolones in a Human Gut Model
  106. Emergence of reduced susceptibility to metronidazole in Clostridium difficile
  107. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model
  108. Editorial Commentary: Decreased Effectiveness of Metronidazole for the Treatment of Clostridium difficile Infection?
  109. In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin
  110. Infection control measures to limit the spread of Clostridium difficile
  111. Clostridium difficile and chlorine-releasing disinfectants
  112. A case-control study of community-associated Clostridium difficile infection
  113. Use of Highly Discriminatory Fingerprinting to Analyze Clusters of Clostridium difficile Infection Cases Due to Epidemic Ribotype 027 Strains
  114. Clostridium difficileInfection: Overview and Update with a Focus on Antimicrobial Resistance as a Risk Factor
  115. Diagnosis of Clostridium difficile-Associated Diarrhea and Odor
  116. Evidence for low risk of Clostridium difficile infection associated with tigecycline
  117. Clostridium difficile: changing epidemiology and new treatment options
  118. Viral gastroenteritis increases the reports of Clostridium difficile infection
  119. Efficacy of Hospital Cleaning Agents and Germicides Against Epidemic Clostridium difficile Strains
  120. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model
  121. S240 Special challenges in C. difficile infection control
  122. P1683 Analysis of reports of Clostridium difficile infection in phase 2 and 3 studies of tigecycline
  123. Clostridium difficile
  124. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model
  125. Comparative Analysis of Prevalence, Risk Factors, and Molecular Epidemiology of Antibiotic-Associated Diarrhea Due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus
  126. Measurement of toxin production by Clostridium difficile
  127. Increased Rate of DNA Recovery from United Kingdom Epidemic Clostridium difficile PCR Ribotype 1 Strains Stored Cryogenically
  128. Molecular Epidemiology of Endemic Clostridium difficile Infection and the Significance of Subtypes of the United Kingdom Epidemic Strain (PCR Ribotype 1)
  129. Erratum to “Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection [Journal of Hospital Infection 2003;54:109–114]”
  130. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea
  131. Detergent versus hypochlorite cleaning and Clostridium difficile infection
  132. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea
  133. Clostridium difficile infection and pseudomembranous colitis
  134. Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection
  135. Evidence to support the existence of subgroups within the UK epidemic Clostridium difficile strain (PCR ribotype 1)
  136. Clostridium difficile
  137. Clostridium difficile
  138. Pulsed-Field Gel Electrophoresis Can Yield DNA Fingerprints of Degradation-Susceptible Clostridium difficile Strains
  139. Prospective evaluation of environmental contamination by Clostridium difficile in isolation side rooms
  140. Molecular epidemiology of endemic Clostridium difficile infection
  141. Ureidopenicillins and risk of Clostridium difficile infection
  142. Letter to the Editor: Virulence of Clostridium difficile toxin A negative strains
  143. Clarithromycin and risk of Clostridium difficile-associated diarrhoea
  144. Hospital disinfectants and spore formation by Clostridium difficile
  145. In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates
  146. Respiratory antibiotic use and Clostridium difficile infection: is it the drugs or is it the doctors?
  147. Value of lysozyme agar incorporation and alkaline thioglycollate exposure for the environmental recovery ofClostridium difficile
  148. Comparison of the Oxoid Clostridium difficile toxin A detection kit with cytotoxin detection by a cytopathic effect method examined at 4, 6, 24 and 48 h
  149. Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam
  150. Incidence and impact of Clostridium difficile infection in the UK, 1993–1996
  151. Treatment of Clostridium difficile infection
  152. Clostridium difficile--setting the scene
  153. Clostridium difficile infection: appendix
  154. Clostridium difficile infections of the gut: the unanswered questions
  155. UK survey of the incidence and impact of Clostridum difficile infection 1993–96
  156. Recurrence of symptoms in Clostridium difficile infection—relapse or reinfection?
  157. Isolation of patients with Clostridium difficile infection
  158. Clostridium difficile toxin A detection on colonies
  159. Activity of nisin against Clostridium difficile
  160. Review article: antibiotic-induced Clostridium difficile infection
  161. Cleaning up Clostridium difficile infection
  162. Financial burden of hospital-acquired Clostridium difficile infection
  163. Clostridium difficile-associated diarrhoea and length of hospital stay
  164. Diarrhoea caused by Clostridium difficile : response time for treatment with metronidazole and vancomycin
  165. Clostridium difficile infection: responses, relapses and re-infections
  166. Ciprofloxacin and Clostridium difficile infection
  167. Copyright
  168. Clostridium Difficile-Associated Diarrhea